Next 10 |
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference. ...
Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors Baruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of th...
ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 s...
2024-05-09 06:06:44 ET More on RxSight RxSight, Inc. (RXST) Q1 2024 Earnings Call Transcript RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation RxSight, Inc. (RXST) Q4 2023 Earnings Call Transcript RxSight announces proposed offeri...
2024-05-08 16:57:21 ET More on RxSight RxSight, Inc. (RXST) Q1 2024 Earnings Call Transcript RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation RxSight, Inc. (RXST) Q4 2023 Earnings Call Transcript RxSight Non-GAAP EPS of -$0.13 be...
2024-05-08 16:32:38 ET More on RxSight RxSight, Inc. (RXST) Q1 2024 Earnings Call Transcript RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation Read the full article on Seeking Alpha For further details see: RxSight files autom...
2024-05-06 22:06:02 ET RxSight, Inc. (RXST) Q1 2024 Earnings Conference Call May 06, 2024 4:30 PM ET Company Participants Oliver Moravcevic – Vice President, Investor Relations Ron Kurtz – President and Chief Executive Officer Shelley Thunen –...
2024-05-06 21:30:02 ET BTIG analyst issues BUY recommendation for RXST on May 6, 2024 08:04PM ET. The previous analyst recommendation was Buy. RXST was trading at $62.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst reco...
2024-05-06 16:15:17 ET More on RxSight RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation RxSight, Inc. (RXST) Q4 2023 Earnings Call Transcript RxSight Non-GAAP EPS of -$0.13 beats by $0.14, revenue of $28.6M beats by $0.74M RxSigh...
News, Short Squeeze, Breakout and More Instantly...
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference. ...
Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors Baruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of th...
ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 s...